Navigation Links
Vectibix® (Panitumumab) Granted Approval for Expanded Indications in the European Union
Date:11/15/2011

ement, superior performance, are easier to administer, or that are otherwise competitive with our products. In addition, while we routinely obtain patents for our products and technology, the protection offered by our patents and patent applications may be challenged, invalidated or circumvented by our competitors and there can be no guarantee of our ability to obtain or maintain patent protection for our products or product candidates. We cannot guarantee that we will be able to produce commercially successful products or maintain the commercial success of our existing products. Our stock price may be affected by actual or perceived market opportunity, competitive position, and success or failure of our products or product candidates. Further, the discovery of significant problems with a product similar to one of our products that implicate an entire class of products could have a material adverse effect on sales of the affected products and on our business and results of operations.

The scientific information discussed in this news release relating to new indications for our products is preliminary and investigative and is not part of the labeling approved by the U.S. FDA, European Medicines Agency (EMA) or similar regulatory bodies for the products. The products are not approved for the investigational use(s) discussed in this news release, and no conclusions can or should be drawn regarding the safety or effectiveness of the products for these uses. Only the FDA, EMA or similar regulatory bodies can determine whether the products are safe and effective for these uses. Healthcare professionals should refer to and rely upon the approved labeling for the products, and not the information discussed in this news release.

(1) Jemal. Global Cancer Statistics. CA CANCER J CLIN 2011;61:69–90

(2) Douillard, JE et al. Randomized, Phase 3 Study (PRIME) of Panitumumab with FOLFOX4 versus FOLFOX4 Alone as First-Line Treatment in Patients With Previ
'/>"/>

SOURCE Amgen Europe GmbH
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Amgen to Appeal CHMP Opinion on Vectibix® (Panitumumab) Use With Chemotherapy in Metastatic Colorectal Cancer in Europe
2. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
3. Pharmion and MethylGene Announce U.S. Orphan Drug Designation Granted for MGCD0103 for the Treatment of Hodgkins Lymphoma
4. Advanced Life Sciences Announces ALS-357 Granted FDA Orphan Drug Designation for Metastatic Melanoma
5. Taxotere(R) (docetaxel) Granted FDA Approval to Treat Locally Advanced Head and Neck Cancer Prior to Chemoradiotherapy and Surgery
6. Aptivus(R) (tipranavir) Capsules Granted Full Approval by the U.S. FDA
7. Authorization for AGENDA Phase 3 Trial of Genasense(R) in Advanced Melanoma Granted by French Regulatory Agency
8. Emphasys Medical Granted Expedited Review From FDA for Zephyr(R) Endobronchial Valve
9. Pharmion and MethylGene Announce Orphan Drug Designation Granted by the European Medicines Agency (EMEA) for MGCD0103 for the Treatment of Acute Myelogenous Leukemia
10. Pharmion and MethylGene Announce U.S. Orphan Drug Designation Granted for MGCD0103 for the Treatment of Acute Myelogenous Leukemia
11. Inclusion of Six-Year Overall Survival Data in the Eloxatin(R) (oxaliplatin injection) Prescribing Information Granted FDA Priority Review
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... India , August 28, 2015 ... Biomarker Market by Tumor (Breast, Lung, Prostate) Type (Protein ... Application (Diagnostic, Drug Discovery, Prognostic) & Geography - Global ... Market is expected to reach around 17,689.0 Million USD ... forecast period of 2015 to 2020. ...
(Date:8/28/2015)... 2015 Research and Markets ... "Investigation Report on China,s Bevacizumab Market ,2010-2019" ... under the trade name of Avastin, bevacizumab injection is ... 2010, it was approved by CFDA to treat metastatic ... China all come from Roche and its ...
(Date:8/28/2015)... , Aug. 28, 2015 ... the addition of the "Investigation Report on China,s ... Tobramycin is a traditional antibiotic whose eye drop ... the treatment of potential infection or inflammation caused by ... China are able to produce tobramycin, among ...
Breaking Medicine Technology:Cancer Biomarkers Market Worth 17,689.0 Million USD by 2020 2Cancer Biomarkers Market Worth 17,689.0 Million USD by 2020 3Cancer Biomarkers Market Worth 17,689.0 Million USD by 2020 4Cancer Biomarkers Market Worth 17,689.0 Million USD by 2020 5Investigation Report on China's Bevacizumab Market 2015-2019 2Investigation Report on China's Tobramycin Market, 2015-2019 2
... NEW YORK, March 14, 2011 Reportlinker.com announces ... in its catalogue: Hepatitis A ... to 2017 http://www.reportlinker.com/p0453473/Hepatitis-A-Preventive-Vaccines---Pipeline-Assessment-and-Market-Forecasts-to-2017.html ... Assessment and Market Forecasts to 2017 ...
... (Nasdaq: PRGO;TASE) today announced that Perrigo Chairman and CEO ... 2011 Global Health Care Conference on Wednesday, March 16, ... Hotel in Miami, FL.  The presentation will be webcast ... Perrigo Company is a leading global healthcare supplier that ...
Cached Medicine Technology:Reportlinker Adds Hepatitis A Preventive Vaccines - Pipeline Assessment and Market Forecasts to 2017 2Reportlinker Adds Hepatitis A Preventive Vaccines - Pipeline Assessment and Market Forecasts to 2017 3
(Date:8/31/2015)... MA (PRWEB) , ... August 31, 2015 , ... Now ... Dietary Guidelines advice to "make at least half your grains whole,” with the majority ... Boston-based non-profit Oldways Whole Grains Council (WGC) released these findings and others ...
(Date:8/31/2015)... ... August 31, 2015 , ... Now through October ... (SM) will be featured on a digital screen projected above New York’s Times ... inspire and promote earlier awareness of the symptoms of ovarian cancer, and earlier ...
(Date:8/31/2015)... ... August 31, 2015 , ... Intellitec Solutions announced they have reached ... board their 8th new staff member in 2015. With the potential for more hiring ... Solutions supports Microsoft Dynamics GP, Dynamics SL, Dynamics CRM and Intacct, and has hired ...
(Date:8/31/2015)... ... August 31, 2015 , ... Adult & Pediatric Dermatology in Greenwood ... patients of the treatments and services available to help them. , The ... and ‘responsive design’ that allows visitors to view the website seamlessly on any desktop ...
(Date:8/31/2015)... (PRWEB) , ... August 31, 2015 , ... GenHart Software, ... it their business to help small businesses operate as efficiently and cost effectively as ... already made an impact in their first year of operation – and the Charleston ...
Breaking Medicine News(10 mins):Health News:Most Americans Now Make Half Their Grains Whole 2Health News:Most Americans Now Make Half Their Grains Whole 3Health News:Most Americans Now Make Half Their Grains Whole 4Health News:Most Americans Now Make Half Their Grains Whole 5Health News:National Ovarian Cancer Coalition Rolls Out "TAKE ACTION. NOT CHANCES. (SM)" Campaign for September, National Ovarian Cancer Awareness Month 2Health News:National Ovarian Cancer Coalition Rolls Out "TAKE ACTION. NOT CHANCES. (SM)" Campaign for September, National Ovarian Cancer Awareness Month 3Health News:Intellitec Solutions Achieves Record Pace for New Hiring 2Health News:Adult & Pediatric Dermatology Launches Responsive Design Website 2Health News:Adult & Pediatric Dermatology Launches Responsive Design Website 3Health News:GenHart Software, LCC Launches Scheduling, Appointment Reminder, Text Marketing Software Designed to Help Businesses Increase Revenue While Decreasing Client Attrition 2Health News:GenHart Software, LCC Launches Scheduling, Appointment Reminder, Text Marketing Software Designed to Help Businesses Increase Revenue While Decreasing Client Attrition 3
... common feature in the hill state of Himachal Pradesh that ... an average//, with the gender ratio falling to be the ... such unchecked prevalence of feticides only one case has been ... Pradesh registers an estimated 7,500 female feticides every year, taking ...
... Smithkline (Britain's biggest drug manufacturer) is being registered for ... vaccine would be marketed for commercial use, by the ... similar vaccine produced by the US pharmaceuticals giant Merck ... It has been proposed to register Cervarix in the ...
... have been suspected to contract meningococcemia, a potentially fatal ... and turn out to be fatal, if not promptly ... caused by the bacteria Neisseria meningitidis, leading to inflammation ... dormant in the upper respiratory tract, without causing any ...
... and Indonesia's Bogor Institute of Agriculture have announced a ... vaccine for animals. The company to be called IPB ... the vaccine in a very short time. ... the company to use its patented reverse genetics technology ...
... withdrawn a reward scheme wherein children were offered vouchers ... used to distribute the McDonald's tokens occasionally to children ... pulled off after the health board said the action ... been in place for many years, but no review ...
... Jharkhand tricked a tribal woman to undergo sterilization, which ... ,A woman from an endangered primitive tribe in ... overzealous doctors, triggering an outcry from social organizations. ... in Dumka, about 450 km from state captial Ranchi, ...
Cached Medicine News:Health News:Female Ratio Drops Alarmingly In Himachal Due To Feticides 2Health News:Delhi Faces Threat of Brain Fever 2Health News:PHC Doctors Tricked Tribal Women To Undergo Sterilization 2
For the quantitative in vitro determination of Lactate Dehydrogenase (LD) in serum and plasma....
For the quantitative in vitro determination of Anti-Streptolysin-O (ASO) in serum....
Latex agglutination slide test for the qualitative and semi-quantitative in vitro determination of Rheumatoid Factor in serum....
For the quantitative in vitro determination of IgE in Human Serum or Plasma....
Medicine Products: